June 19, 2009 (Copenhagen, Denmark) — "Real-life" studies in patients with lupus nephritis show that intravenous (IV) cyclophosphamide is superior to oral cyclophosphamide as induction therapy and ...

Adicet Bio (NASDAQ:ACET) on Wednesday said that the U.S. Food and Drug Administration has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or ...

Class III/IV lupus nephritis, higher C-reactive protein levels, and the presence of U1-RNP antibodies were linked to lower bone mineral density among patients with systemic lupus erythematosus. Lupus ...

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for ...

Please provide your email address to receive an email when new articles are posted on . Twelve years is a long time by most measures, but in a field has rapidly changing as lupus nephritis research, ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving ...

Glomerular disease in LN is a dynamic process with the potential for glomerular lesions to transform from one pattern to another. 1-4 Adjacent glomeruli may show different degrees of involvement. The ...

In a new study, researchers found low glomerular filtration rate and chronic histologic damage predicted eGFR loss in people ...

The American College of Rheumatology last published recommendations for managing lupus nephritis (LN) in 2012. Since then, targeted treatments including belimumab (Benlysta) and voclosporin (Lupkynis) ...

When added to standard care, more lupus nephritis patients achieved complete remissions with obinutuzumab (Gazyva) than with placebo. Treatment was added to mycophenolate mofetil and glucocorticoids.

CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to share that on May 6, 2026, Canada's Drug Agency (CDA-AMC) ...

The MarketWatch News Department was not involved in the creation of this content. The lupus nephritis market is poised for growth, driven by rising disease prevalence, advancements in therapeutics ...